Navigation Links
CHERISH trial demonstrates efficacy of tocilizumab in juvenile idiopathic arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism shows that tocilizumab is efficacious and leads to a sustained clinically meaningful improvement in children with polyarticular Juvenile Idiopathic Arthritis (pcJIA).

Tocilizumab is a humanized recombinant antibody, which blocks the receptors where interleukin-6 (IL-6) attaches to the surface of cells. When IL-6 is unable to attach to these cells, they are prevented from driving inflammation. Elevated serum and joint fluid IL-6 levels have been shown to be associated with disease activity in patients with pcJIA.1

"JIA is a chronic arthritis occurring in 1 in every 1,000 children. With no known cause, it can lead to joint damage and permanent disability. These data show that tocilizumab rapidly improves signs and symptoms of pcJIA, with meaningful clinical responses maintained in a large proportion of patients at week 40," said lead author Dr. Fabrizio De Benedetti of the IRCCS Ospedale Pediatrico Bambino Gesu, Rome.

Speaking on behalf of the Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG), who had overseen this study, Dr. De Benedetti concluded that "these data suggest that tocilizumab is going to be a novel biologic part of the therapeutic armamentarium for pcJIA."

CHERISH is a two-year, 3-part trial being conducted at 58 centres across 15 countries. Patients aged 2-17 years were included in the study if they had active pcJIA for at least 6 months and had failed to respond to methotrexate (a cornerstone of therapy worldwide for this condition).

Part 1 of the study was a 16-week open-label phase in which 188 patients received tocilizumab every four weeks. The 166 patients who achieved at least a 30% improvement in symptoms and signs of pcJIA (an JIA ACR30* response) went on to part 2, which was a 24-week study in which patients were randomised to continue on the same dose of tocilizumab or to receive placebo. Part 3 is an ongoing open-label study.

For the primary end point of ACR30 flare, fewer patients in the tocilizumab group than in the placebo group experienced a flare by week 40 (25.6% vs. 48.1%) and JIA ACR30/50/70* responses were significantly higher with tocilizumab than placebo, with as many as 65% of the children attaining an ACR70 response.

Dosing of tocilizumab was based on the patient's body weight (BW): with a BW ≥30 kg, the dose was 8 mg/kg [n=119]; with a BW <30 kg, patients were randomly assigned to 8 mg/kg [n=34] or 10 mg/kg [n=35].

"The degree of improvement at week 16 was lower for each of the endpoints for patients under 30 kg on 8 mg/kg tocilizumab than in the other two treatment groups. The data therefore support the efficacy of tocilizumab in pcJIA using a monthly regimen at doses of 8 mg/kg if BW 30 kg or more, and 10 mg/kg if BW under 30 kg," Dr. De Benedetti added.

Patients were also taking background medications, such as methotrexate and oral corticosteroids (79% and 46% respectively).

Tocilizumab's safety profile was consistent with that found in other tocilizumab-treated patients.2 At the safety data cut, 184 patient years of follow-up had occurred in the 188 patients enrolled. Infection was the most common adverse event (164/100 patient years) and serious adverse event (4.9/100 patient years). Liver enzyme (ALT/AST) elevations ≥3 upper limit of normal occurred in 3.7 % / <1% of patients, neutropenia (<1000 cells/mm3) in 3.7% of patients, thrombocytopenia (<50,000 cells/mm3) in 1.1% of patients. An elevation of LDL-cholesterol ≥110 mg/dl was reported in 11.4% of patients who received tocilizumab.


'/>"/>
Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Brain Tumor Vaccine Shows Promise in Early Trial
2. URMC clinical trial tests new regimen for hypertension
3. Analysis Finds Clinical Trials Often Small, of Poor Quality
4. US spends far more for health care than 12 industrialized nations, but quality varies
5. New Weight-Loss Drug Shows Promise in Trial
6. Palpitations are predictive of future atrial fibrillation
7. Trial Set to See if Drug Can Prevent Alzheimers
8. Experts call for clinical trials to test non-skeletal benefits of vitamin D
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. Canada should significantly increase its funding of randomized clinical trials
11. Alzheimers vaccine trial a success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy to announce ... been available via Amazon.com. This new style of nail clipper has a wider jaw ... is approximately 4mm and the actual handle is 2.5mm thick to accommodate the cutting ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating web ... control the style of their project," said Christina Austin - CEO of Pixel Film ... intros created exclusively for use in Final Cut Pro X. Pixel Film Studios’ minimalistic ...
(Date:5/28/2016)... ... 2016 , ... "Color Grading media can be time consuming but with FCPX ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... color grades to their footage. A LUT is a Lookup Table that contains a ...
(Date:5/28/2016)... ... ... and a half of planning the Multiple Pathways of Recovery Conference , CCAR is ... was held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa . ... many pathways individuals use to get into and sustain their recovery. Pathways of recovery ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... May 25, 2016 According to ... Type (3D, 2D, 4D), by Therapeutic Area (Oncology, Cosmeceutical/Plastic ... User (Medical Device Manufacturers, Hospitals/ Clinics) - Forecast to ... Medical Animation Market for the forecast period of 2016 ... 301.3 Million by 2021 from USD 117.3 Million in ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
Breaking Medicine Technology: